NCT06659549

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2025-01-10Est. Completion: 2027-03-30

Enrollment target: 110 participants

Locations

Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
Bay Area Retina Associates, Walnut Creek, California, United States
Cumberland Valley Retina Consultants, Hagerstown, Maryland, United States
Ophthalmological Center After S.V. Malayan, Yerevan, Armenia
Centre Rétine Gallien, Bordeaux, France
Hopital de La Croix-Rousse Service D'Ophtalmologie Groupement Hospitalier Nord Hospices Civils de Lyon, Lyon, France
Centre Monticelli Paradis d'Ophtalmologie, Marseille, France
Centre Ophtalmologique Odéon, Paris, France
Centre médico-chirurgical de Touraine, Tours, France
Akhali Mzera Limited, Tbilisi, Georgia
Caucasus Medical Centre LLC, Tbilisi, Georgia
Universitäts-Augenklinik Bonn, Bonn, Germany
Universitätsklinikum Freiburg Klinik für Augenheilkunde, Freiburg im Breisgau, Germany
Medizinische Hochschule Hannover Augenklinik, Hanover, Germany
Dietrich Bonhoeffer Klinikum, Neubrandenburg, Germany
Universitätsklinikum Tübingen, Department für Augenheilkunde., Tübingen, Germany

Intermediate AMD

The goal of this study is to demonstrate that photothermal therapy with the individually dosed treatment plan proposed b…

Detmold, GermanyEst. completion Dec 2027

Geographic Atrophy

This is a sequential Phase 1/2, two-part, multicenter study on safety, tolerability, and efficacy of one-time intravitre…

Peoria, United StatesEst. completion Oct 13, 2027

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.